Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Background Preterm birth remains a common cause of neonatal mortality, with a disproportionately high burden in low-income and middle-income countries. Meta-analyses of low-dose aspirin to prevent pre-eclampsia suggest that the incidence of preterm birth might also be decreased, particularly if initiated before 16 weeks of gestation.Methods ASPIRIN was a randomised, multicountry, double-masked, placebo-controlled trial of low-dose aspirin (81 mg daily) initiated between 6 weeks and 0 days of pregnancy, and 13 weeks and 6 days of pregnancy, in nulliparous women with an ultrasound confirming gestational age and a singleton viable pregnancy. Participants were enrolled at seven community sites in six countries (two sites in India and one site each in the Democratic Republic of the Congo, Guatemala, Kenya, Pakistan, and Zambia). Participants were randomly assigned (1:1, stratified by site) to receive aspirin or placebo tablets of identical appearance, via a sequence generated centrally by the data coordinating centre at Research Triangle Institute International (Research Triangle Park, NC, USA). Treatment was masked to research staff, health providers, and patients, and continued until 36 weeks and 7 days of gestation or delivery. The primary outcome of incidence of preterm birth, defined as the number of deliveries before 37 weeks' gestational age, was analysed in randomly assigned women with pregnancy outcomes at or after 20 weeks, according to a modified intention-to-treat (mITT) protocol. Analyses of our binary primary outcome involved a Cochran-Mantel-Haenszel test stratified by site, and generalised linear models to obtain relative risk (RR) estimates and associated confidence intervals. Serious adverse events were assessed in all women who received at least one dose of drug or placebo. This study is registered with ClinicalTrials.gov, NCT02409680, and the Clinical Trial Registry-India, CTRI/2016/05/006970.Findings From March 23, 2016 to June 30, 2018, 14 361 women were screened for inclusion and 11 976 women aged 14-40 years were randomly assigned to receive low-dose aspirin (5990 women) or placebo (5986 women). 5780 women in the aspirin group and 5764 in the placebo group were evaluable for the primary outcome. Preterm birth before 37 weeks occurred in 668 (11·6%) of the women who took aspirin and 754 (13·1%) of those who took placebo (RR 0·89 [95% CI 0·81 to 0·98], p=0·012). In women taking aspirin, we also observed significant reductions in perinatal mortality (0·86 [0·73-1·00], p=0·048), fetal loss (infant death after 16 weeks' gestation and before 7 days post partum; 0·86 [0·74-1·00], p=0·039), early preterm delivery (<34 weeks; 0·75 [0·61-0·93], p=0·039), and the incidence of women who delivered before 34 weeks with hypertensive disorders of pregnancy (0·38 [0·17-0·85], p=0·015). Other adverse maternal and neonatal events were similar between the two groups.Interpretation In populations of nulliparous women with singleton pregnancies from low-income and middle-income countries, low-dose aspirin initiated between 6 weeks and 0 days of gestation and 13 weeks and 6 days of gestation resulted in a reduced incidence of preterm delivery before 37 weeks, and reduced perinatal mortality.Funding Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, a meta-analysis and an additional trial demonstrate that low-dose aspirin <100 mg is not effective in reducing preeclampsia.Low-dose aspirin >100 mg is required (117-119).”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [119]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blencowe, H., Cousens, S., Oestergaard, M. Z., Chou, D., Moller, A.-B., Narwal, R., Adler, A., Vera Garcia, C., Rohde, S., Say, L., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60820-4 · Cited by 4,568
Liu, L., Johnson, H. L., Cousens, S., Perin, J., Scott, S., Lawn, J. E., Rudan, I., Campbell, H., Cibulskis, R., Li, M., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60560-1 · Cited by 3,934
Liu, L., Oza, S., Hogan, D., Chu, Y., Perin, J., Zhu, J., Lawn, J. E., Cousens, S., Mathers, C., & Black, R. E. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31593-8 · Cited by 3,453
Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia
Rolnik, D. L., Wright, D., Poon, L. C., O’Gorman, N., Syngelaki, A., de Paco Matallana, C., Akolekar, R., Cicero, S., Janga, D., Singh, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704559 · Cited by 2,287
Villar, J., Ismail, L. C., Victora, C. G., Ohuma, E. O., Bertino, E., Altman, D. G., Lambert, A., Papageorghiou, A. T., Carvalho, M., Jaffer, Y. A., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60932-6 · Cited by 2,281
Alkema, L., Chou, D., Hogan, D., Zhang, S., Moller, A.-B., Gemmill, A., Fat, D. M., Boerma, T., Temmerman, M., Mathers, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00838-7 · Cited by 2,261
Long-Term Medical and Social Consequences of Preterm Birth
Moster, D., Lie, R. T., & Markestad, T. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706475 · Cited by 1,402
Progesterone and the Risk of Preterm Birth among Women with a Short Cervix
Fonseca, E. B., Celik, E., Parra, M., Singh, M., & Nicolaides, K. H. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067815 · Cited by 1,086
Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data
Askie, L. M., Duley, L., Henderson-Smart, D. J., & Stewart, L. A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60712-0 · Cited by 1,020
Cited by
Chappell, L. C., Cluver, C. A., Kingdom, J., & Tong, S. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32335-7 · Cited by 925
Parikh, N. I., Gonzalez, J. M., Anderson, C. A. M., Judd, S. E., Rexrode, K. M., Hlatky, M. A., Gunderson, E. P., Stuart, J. J., Vaidya, D., & On behalf of the American Heart Association Council on Epidemiology and Prevention; Council on Arteriosclerosis, T. A. V. B. C. O. C. A. S. N. A. T. S. C. (2021) · Circulation · doi:10.1161/cir.0000000000000961 · Cited by 743
15. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s015 · Cited by 504
Prevention of preeclampsia with aspirin
Rolnik, D. L., Nicolaides, K. H., & Poon, L. C. (2022) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2020.08.045 · Cited by 390
Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women
Cho, L., Davis, M., Elgendy, I., Epps, K., Lindley, K. J., Mehta, P. K., Michos, E. D., Minissian, M., Pepine, C., Vaccarino, V., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.060 · Cited by 347
Metadata
- Authors
- Hoffman, M. K., Goudar, S. S., Kodkany, B. S., Metgud, M., Somannavar, M., Okitawutshu, J., Lokangaka, A., Tshefu, A., Bose, C. L., Mwapule, A., Mwenechanya, M., Chomba, E., Carlo, W. A., Chicuy, J., Figueroa, L., Garces, A., Krebs, N. F., Jessani, S., Zehra, F., Saleem, S., Goldenberg, R. L., Kurhe, K., Das, P., Patel, A., Hibberd, P. L., Achieng, E., Nyongesa, P., Esamai, F., Liechty, E. A., Goco, N., Hemingway-Foday, J., Moore, J., Nolen, T. L., McClure, E. M., Koso-Thomas, M., Miodovnik, M., Silver, R., Derman, R. J., Achieng, E., Bauserman, M., Bose, C., Bucher, S., Carlo, W., Charantimath, U. S., Chicuy, J., Chomba, E., Das, P., Derman, R., Esamai, F., Figueroa, L., Ganachari, M., Garces, A., Goco, N., Goldenberg, R., Goudar, S., Hemingway-Foday, J., Hibberd, P., Hoffman, M., Honnungar, N. V., Jessani, S., Kavi, A., Kodkany, B., Koso-Thomas, M., Krebs, N., Kumar Shashikanth, Y., Kurhe, K., Liechty, E., Lokangaka, A., MacGuire, E., Mallapur, A. A., McClure, E., Metgud, M., Miodovnik, M., Moore, J., Mwapule, A., Mwenechanya, M., Naqvi, F., Naqvi, S., Nathan, R., Nolen, T., Nyongesa, P., Okitawutshu, J., Parepalli, S., Patel, A., Ramadurg, U. Y., Saleem, S., Silver, R., Somannavar, M., Soomro, Z., Tshefu, A., Vernekar, S. S., Wallace, D., & Zehra, F.
- Affiliations
- RTI International (US)
- Aga Khan University (PK)
- Columbia University (US)
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 395
- Issue
- 10220
- Pages
- 285-293
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC7168353
- OpenAlex
- W3002210726
- Cited by
- 360
- References
- 34
- Citations by year
- 2026: 48 · 2025: 40 · 2024: 71 · 2023: 59 · 2022: 53 · 2021: 60 · 2020: 27
- FWCI
- 35.68
- Type
- journal article
- Language
- en
- Update notices
- erratum (2020-03-21)
- Open access
- green
- europepmc.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- The Medicine Forum (submittedVersion)
- Funders
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (UG1HD076461, U10HD076474, U10HD078437, U10HD078438, U10HD078439, U10HD076461, U10HD076465, U10HD076457, UG1HD076465, UG1HD076474, UG1HD076457, U24HD092094, UG1HD078439, UG1HD078437, UG1HD078438)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Preterm Birth and Chorioamnionitis
- Health Sciences › Medicine › Obstetrics and Gynecology › Pregnancy and preeclampsia studies
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Global Maternal and Child Health
- Keywords
- low-dose aspirin, preterm birth prevention, nulliparous women, singleton pregnancy, preterm birth, low- and middle-income countries, serious adverse events
- MeSH terms
- Adolescent, Adult, Aspirin, Blood Pressure, Developing Countries, Double-Blind Method, Female, Humans, Pre-Eclampsia, Pregnancy, Pregnancy Outcome, Delivery, Obstetric, Premature Birth, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(19)32973-3
- The paper
- Hoffman, M. K., Goudar, S. S., Kodkany, B. S., Metgud, M., Somannavar, M., Okitawutshu, J., Lokangaka, A., Tshefu, A., Bose, C. L., Mwapule, A., Mwenechanya, M., Chomba, E., Carlo, W. A., Chicuy, J., Figueroa, L., Garces, A., Krebs, N. F., Jessani, S., Zehra, F., . . . Zehra, F. (2020). Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(19)32973-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.